Innovation supply chain model risks "teaching to the test"

05/2/2013 | Xconomy

Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
PacificSource
Boise, ID